Sigilon Therapeutics is a multidisciplinary biotechnology company which specializes in creating immune privileged products to address unmet clinical needs. Our mission at Sigilon Therapeutics is to develop improved treatments for chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the foreign body response (fibrosis). Treatments based on the Sigilon Therapeutics technology platform will act as responsive “living therapeutics” that can provide more natural control for diseases currently treated with intermittent injection or infusion. The company is based in Kendall Square in Cambridge, MA and is funded by Flagship Pioneering. Please forward your application via email to email@example.com
The ideal candidate will transition easily into the tissue culture of primary cells and cell lines as well as the stable transfection and selection of engineered cell lines and more.